Research Analysts Issue Forecasts for TNGX FY2026 Earnings

Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for Tango Therapeutics in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst E. Schmidt anticipates that the company will earn ($1.58) per share for the year. The consensus estimate for Tango Therapeutics' current full-year earnings is ($1.19) per share.

Separately, HC Wainwright reissued a "buy" rating and issued a $13.00 price objective on shares of Tango Therapeutics in a research note on Monday, April 14th. Six analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of "Buy" and an average price target of $12.20.

Tango Therapeutics Price Performance

Shares of NASDAQ:TNGX traded up $0.07 during midday trading on Wednesday, hitting $4.81. 1,105,372 shares of the company's stock were exchanged, compared to its average volume of 1,463,251. Tango Therapeutics has a 12 month low of $1.03 and a 12 month high of $12.02. The company has a market cap of $521.38 million, a PE ratio of -4.08 and a beta of 1.24. The stock has a 50 day moving average price of $1.88 and a 200-day moving average price of $2.40.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.02). Tango Therapeutics had a negative net margin of 284.42% and a negative return on equity of 49.64%. The business had revenue of $5.39 million during the quarter, compared to analyst estimates of $6.73 million.

Institutional Investors Weigh In On Tango Therapeutics

Hedge funds have recently made changes to their positions in the business. Acadian Asset Management LLC increased its holdings in Tango Therapeutics by 96.6% during the first quarter. Acadian Asset Management LLC now owns 973,309 shares of the company's stock worth $1,327,000 after buying an additional 478,203 shares during the last quarter. Jane Street Group LLC grew its position in shares of Tango Therapeutics by 270.6% during the 1st quarter. Jane Street Group LLC now owns 352,897 shares of the company's stock valued at $483,000 after acquiring an additional 257,668 shares during the period. Woodline Partners LP lifted its stake in Tango Therapeutics by 28.3% in the first quarter. Woodline Partners LP now owns 506,188 shares of the company's stock valued at $693,000 after purchasing an additional 111,791 shares during the last quarter. Dynamic Technology Lab Private Ltd grew its holdings in Tango Therapeutics by 139.7% during the first quarter. Dynamic Technology Lab Private Ltd now owns 25,801 shares of the company's stock valued at $35,000 after purchasing an additional 15,037 shares during the period. Finally, Jacobs Levy Equity Management Inc. increased its position in Tango Therapeutics by 42.6% in the first quarter. Jacobs Levy Equity Management Inc. now owns 737,955 shares of the company's stock worth $1,011,000 after buying an additional 220,529 shares during the last quarter. 78.99% of the stock is currently owned by institutional investors.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.